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Both estrogen receptors (ER) alpha (ERα) and beta (ERβ) are localized in the nucleus, plasma membrane, and mitochondria, where they
mediate the different physiological effects of estrogens. It has been observed that the relative subcellular localization of ERs is altered in several
cancer cells. We have demonstrated that MCF-10F cells, the immortal and non-tumorigenic human breast epithelial cells (HBEC) that are ERα-
negative and ERβ-positive, are transformed in vitro by 17β-estradiol (E2), generating highly invasive cells that are tumorigenic in severe
combined immunodeficient mice. E2-transformed MCF-10F (trMCF) cells exhibit progressive loss of ductulogenesis, invasive (bsMCF) and
tumorigenic (caMCF) phenotypes. Immunolocalization of ERβ by confocal fluorescent microscopy and electron microscopy revealed that ERβ is
predominantly localized in mitochondria of MCF-10F and trMCF cells. Silencing ERβ expression with ERβ-specific small interference RNA
(siRNA-ERβ) markedly diminishes both nuclear and mitochondrial ERβ in MCF-10F cells. The ERβ shifts from its predominant localization in
the mitochondria of MCF-10F and trMCF cells to the nucleus of bsMCF cells, becoming predominantly nuclear in caMCF cells. Furthermore, we
demonstrated that the mitochondrial ERβ in MCF-10F cells is involved in E2-induced expression of mitochondrial DNA (mtDNA)-encoded
respiratory chain (MRC) proteins. This is the first report of an association of changes in the subcellular localization of ERβ with various stages of
E2-induced transformation of HBEC and a functional role of mitochondrial ERβ in mediating E2-induced MRC protein synthesis. Our findings
provide a new insight into one of the potential roles of ERβ in human breast cancer.
© 2007 Elsevier B.V. All rights reserved.Keywords: Estrogen receptor β; Human breast epithelial cell; Mitochondrial estrogen receptor; Mitochondrial respiratory chain protein; Specific siRNA for ERβ1. Introduction
Estrogens, mainly 17β-estradiol (E2), play a key etiological
role in human breast cancer [1–3]. It is generally accepted that
estrogens act on breast cells via their specific estrogen receptor
(ER) alpha (ERα) and beta (ERβ) [4–8], which are encoded by
different genes and mediate the biological and carcinogenic
effects of estrogens. Both ERα and ERβ act as transcriptional
factors. The ligand-activated receptors bind to DNA and
regulate expression of estrogen responsive genes [9,10].
While both ERα and ERβ share a number of structural and⁎ Corresponding author. Tel.: +1 215 214 3922; fax: +1 215 728 2899.
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doi:10.1016/j.bbamcr.2007.05.008functional similarities, they differ somewhat in term of
subcellular localization and transactivation of certain estrogen
responsive genes [11,12]. The role of ERα in breast cancer has
been extensively studied and its expression in breast cancer cells
is generally regarded as a reliable marker for predicting
response to hormone therapy [13–16]. Although ERβ is widely
present in human breast cells, breast cancer tissues and cell lines
[17,18], in spite of extensive studies since its discovery, the
clinical value as a breast cancer prognostic factor and its precise
role of ERβ in the initiation and progression of breast cancer
have not fully clarified [10,17,19].
Both ERα and ERβ belong to the super-family of type I
nuclear receptors that reside in cytosol of E2-target cells and
translocate to the nucleus after ligand binding where they are
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estrogen responsive genes [20,21]. There is increasing evidence
that ERs, particularly ERα, are present in the plasma membrane,
from where they mediate a number of “rapid, non-genomic
effects” of E2 through modification of several signal pathways
[22–24]. In addition to its localization in nuclei, plasma
membrane and cytosol, ERβ has been known to be present in
mitochondria of estrogen-targeted cells, including human breast
cancer MCF-7 cells [25–34]. The overall physiological effects
of E2/ERβ in normal cells may require the balanced and
coordinate contributions from each one of these ERβ pools. It is
quite likely that altered sub-cellular localization could result in
persistent over-abundance of ERβ in one pool and/or deficiency
in other pools, which may alter physiological and pathological
activities that lead to diseases. In fact, differences in the
cytoplasmic and nuclear levels of ERβ have been observed
between normal epithelial cells of breast, colon, and endome-
trium and their corresponding neoplastic lesions [35–40]. These
observations prompted us to investigate whether the differences
in subcellular distribution of ERβ between normal and
neoplastic cells might play a mechanistic role in estrogen-
induced breast cancer.
Although the role played by specific localization of ERα to
plasma membrane [23,41–46] and nucleus [47] has been
relatively well investigated, how ERα and ERβ are imported to
the mitochondria and what are the physiological and patholo-
gical roles of the altered sub-cellular distribution of ERβ in the
pathogenesis of breast cancer are not as yet understood. For
addressing this important issue, we have capitalized in our in
vitro/in vivo model of E2-induced transformation and tumor-
igenesis of human breast epithelial cells [3,48]. This model
represents a step-wise progression of E2-induced transformation
of MCF-10F cells, as determined by the expression of loss of
ductulogenesis, increased invasiveness in a Matrigel system,
and tumorigenesis in severe combined immunodeficient (SCID)
mice [49,50]. Because MCF-10F cells are ERα negative and
ERβ-positive [3,49], they provide a valuable model for
investigating whether changes in subcellular localization of
ERβ occur during the initiation and progression of E2 -induced
transformation of HBEC. Results reported here demonstrate for
the first time that in this in vitro/in vivomodel ERβ shifts from a
predominantly mitochondrial localization in normal and early
transformed cells to a nuclear localization in association with
the expression of progressive stages of cell transformation and
that mitochondrial ERβ is involved in E2-induced mtDNA
transcription.2. Materials and methods
2.1. Cell lines
The following cell lines were utilized: (1) MCF-10F parent cells, which
are immortal human breast epithelial cells negative to ERα and positive to
ERβ [49,51]; (2) transformed MCF-10F cells (trMCF) generated from MCF-
10F cells with treatment of 70 nM E2 twice a week for 2 weeks. These cells
exhibited anchorage independent growth, colony formation in agar methocel,
and loss of ductulogenic capacity in collagen gel, all phenotypes indicative ofneoplastic transformation [3,48]; (3) invasive MCF-10F (bsMCF) developed
from trMCF; TrMCF cells exhibited high invasiveness in Matrigel and 4)
Tumorigenic MCF-10F (caMCF); These cells were derived from tumors that
were developed by transplanting bsMCF into SCID mice and possessed
tumor-forming capability [3,48–50]. They were routinely cultured at 37 °C in
a humidified atmosphere containing 5% CO2 in DMEM/F-12 medium
supplemented with 5% horse serum, 2 mmol/L glutamine, 100 units/mL
penicillin, and 100 μg/ml streptomycin prepared by the Fox Chase Cancer
Center Tissue Culture Facility (Philadelphia, PA). ERβ-positive MCF-7 and
T47D cells, and ERβ-negative MBA-MD-435 cells were obtained from the
American Type Culture Collection (Rockville, MD) and used as positive and
negative controls, respectively.
2.2. Chemicals, reagents and materials
17β-estradiol (E2) was obtained from Steraloids Inc (Newport, RI). The
ERβ-selective ligand, diarylpropionitrile (DPN) and ERα-selective ligand,
propylpyrazole triol (PPT), were purchased from Tocris (Ellisville, MO). The
protease inhibitors leupetin, aprotinin, phenolmethylsulfyloride and DL-
dithiothreitol were obtained from Sigma Chemical Co. (St. Louis, MO).
Recombinant human ERβ (rhERβ) (59.7 kDa), rhERα (66 kDa) and tris-
glycine gels (4–12%) were obtained from Invitrogen (Carlsbad, CA).
Reagents for western blot analysis (SDS-PAGE running buffer, non-fat dry
milk, pre-stained SDS-PAGE standard protein markers, nitrocellullose
membranes and the Bio-Rad protein assay kit) were obtained from Bio-Rad
Laboratories (Hercules, CA).
2.3. Antibodies
Four anti-ERβ antibodies were used in this study: 1) A rabbit polyclonal
anti-ERβ raised against the ligand binding domain (LBD)(amino acid 320–527)
of human ERβ [8] was kindly provided by Dr. Jan-Åke Gustafsson (Karolinska
Institute, NOVUM; Huddinge, Sweden) and designated ERβ Ab(SW). This
antibody was affinity purified with human ERβ LBD and pre-absorbed with a
human ERα LBD polypeptide. It was reactive with ERβ from mouse, rat,
monkey and human, negative in ERβ knock out mice (Jan-Åke Gustafsson,
personal communication) and detected specifically a 60-kDa ERβ protein in
rodent mammary gland [52]. In this study, ERβ Ab(SW) was used for Western
blot (Fig. 1B) and immunostaining and confocal fluorescent microscopy
(Fig. 5). 2) ERβ antibody (H-150), raised against amino acids 1–150 of the
amino-terminal of human ERβ, was obtained from Santa Cruz Biotechnology
Inc. (Santa Cruz, CA) and designated as ERβ Ab (SC). This antibody has been
extensively used for investigating the subcellular localization of ERβ in a
number of cells and tissues [25,29,31,33,53,54], and detected wild-type
ERβ(ERβ-1) and ERβ variants (e.g. ERβ-2, ERβ-4 and ERβ-5) over-
expressing in HEK293 cells [55]. In this work, ERβ Ab (SC) was utilized for
Western Blots (Fig. 1A), immunostaining and Confocal fluorescent microscopy
(Fig. 2; Fig. 3A and C) and immunogold electron microscopy (Fig. 4B). 3)
Rabbit monoclonal antibody against a synthetic peptide corresponding to amino
acids 468–485 (SSTEDSKNKESSQNLQSQ) of rat ERβ, which has 14/18
amino acids identical to human ERβ, was obtained from Upstate Signaling
Solutions (Lake Placid, NY) and designated ERβ Ab (Upstate). This antibody
was utilized for Western blot (Fig. 7A), immunostaining/confocal fluorescent
microscopy (Fig. 3D) and immunogold electron microscopy (Fig. 4A). 4) A
monoclonal anti-ERβ antibody [56] raised against the NH2-terminal amino acid
residues 1–146 of ERβ [57] was obtained from Genetic Text Inc. (San Antonio,
TX) and designated as ERβ Ab(GT). Its specificity for ERβ was previously
tested [56,58,59]. Additional antibodies used were an anti-human ERα antibody
H-184, polyclonal anti-human histone H-1 and anti heat shock p60 (hsp60), a
secondary goat anti-rabbit IgG-linked to horseradish peroxidase (HRP), goat
anti-mouse IgG-HRP, and pre-immune rabbit IgG, all were obtained from Santa
Cruz Biotechnology Inc. Monoclonal antibody for human cytochrome c oxidase
subunit II (COII), secondary antibodies goat-anti rabbit IgG tagged with red
fluorescent dye Alexa Fluor 594 (Fluor 594) and goat-anti mouse IgG tagged
with green fluorescent dye Fluor-488 (Fluor 488), MitoTracker CNXRos, and
prolong Gold Antifade reagent were obtained from Molecular Probes (Eugene,
OR). ECL detection reagents were obtained from Amersham Biosciences (Little
Chalfont Buckinghamshire, England). KODAK BioMax XAR films were
Fig. 1. Western blots performed for determining the ERβ status in MCF-10F, trMCF, and bsMCF and caMCF cells, using MCF-7 and T47D cells as controls. Purified
rhERβ was included as positive controls for ERβ. (A) ERβ Abs (SC) antibody reacted with rhERβ (lane 1), and with a protein similar to rhERβ (arrow) in protein
extracts prepared from MCF-10F (lane 2), trMCF (lane 3), baMCF (lane 4), caMCF (lane 5) and MCF-7 cells (lane 6). A similarly duplicated membrane was probed
with antibody for Hsp60 and used as a control for protein loading (lower panel). (B) Western blots using ERβ AB (SW). This showed similar reactivity with rhERβ
(lane 1) and with protein samples from the indicated cells. A similarly duplicated membrane probed with antibody for Hsp60 was used as a control for protein loading.
Molecular Markers are shown in left-hand side.
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expression, small interference RNA (siRNA) transfection reagent (SiLMPOR-
TOR™), ERβ-specific siRNA (siRNA SAMRTpool ESR2) and non-specific
siRNA were obtained from Dharmacon, Inc./Upstate Cell Signaling Solution
(Lake Placid, NY).
2.4. Preparation of total cellular homogenates
Preparation of total cellular extracts were performed as described [25,27].
The amounts of proteins were determined by using Bio-Rad Protein Assay kit
according to manufacturer's instructions using bovine serum albumin (BSA) as
standard.
2.5. Northern blot analysis
Preparation of cDNA probes for mtDNA-encoded genes (COI, CO II and
ND1), total RNA isolation and Northern blot analysis were performed as
described previously [25,60].
2.6. Western blot analyses
Western blots for ERβ were performed as previously described
[25,27,28]. Briefly, total homogenate (100 μg/lane) from each cell line,
along rhERβ (15 ng/lane), were separated via 4–12% tri-glycine SDS-PAGE
at 150 V for 2 h and transferred to nitrocellulose membranes at 25 V at 4 °C
for 2 h. The membranes were blocked with 4% non-fat milk in phosphate-
based saline-tween (PBST) buffer for 1 h, washed with PBST solution and
incubated with the previously described antibodies ERβ Ab (SW) (1:1500),
ERβ Ab (SC) (1:1000), ERβ Ab (GT) (1:1000), and ERβ-Ab (Upstate)
(1:1000), followed by the corresponding secondary antibodies anti-rabbit IgG
or anti-mouse IgG-HRP (1:1000) and detected with ECL detection reagents.
A similar duplicated membrane was probed with anti-Hsp60 antibody and
used as a control for protein loading.
2.7. Immunolocalization of ERβ using laser confocal scanning
fluorescent microscopy (LCSFM)
MCF-10F, trMCF, bsMCF and caMCF cells were grown on four-well
LabTek chamber slides; When they reached 50% confluence they were stainedwith MitoTracker CNXRos (100 nM) for 30 min and fixed with 100% ethanol at
−20 °C for 10 min, followed by 100% acetone at −20 °C for 5 min. The cells
were permeabilized by incubation with 0.5% tritone-100 in PBST buffer for
10 min, blocked for 1 h with 5% non-fat milk in PBST at room temperature for
1 h, washed three times with 1× PBST (5 min each) and incubated with the
indicated ERβ antibodies (1:100), followed by incubation with the correspond-
ing secondary antibodies (goat anti-rabbit IgG or goat anti-mouse IgG) tagged
with green fluorescent fluor 488 (1:250) and washed extensively with PBST.
The cells were mounted using the Prolong Gold Anti-fade reagent. The
specificity of each primary antibody was determined by using one or both
secondary antibodies without primary antibody or with pre-immune rabbit IgG.
The dilution of each antibody was optimized to minimize non-specific
absorption of fluorescent antibody, ensure separation of fluorescent signals,
and optimize fluorosphore concentrations.
2.8. Silencing ERβ expression with small interference RNA
(siRNA)-ERβ
Silencing ERβ expression with siRNA-ERβ was performed using ERβ
SiRNA/siAb TM Assay Kit (Upstate Cell Signalling Solution, Billerica, MA)
according to manufacturer's recommended procedures. Briefly, MCF-10F cells
were seeded in 6 well-tissue culture plates (35 mm×10 mm) (Corning
Incorporated, Corning, NY) for 24 h until the cells had reached 50% confluence.
For confocal fluorescent microscopy examination, the cells were seeded in four-
well LabTek chamber sliders as described above. Before transfection, the cells
were placed in 0.93 ml of DMEM/F12 (serum free) medium; 5 μl of
silMPORTER siRNA transfection reagent were mixed gently with 25 μl serum
free medium/per well. Briefly, siRNA-ERβ or non-specific siRNA solution was
prepared by mixing 25 μl siRNA diluents, 10 μl serum free medium, and
different doses of siRNA-ERβ (50, 100 and 150 pmol/ml medium), or the same
doses of non-specific siRNA, and stirred gently. This solution was added to the
silMPORTER siRNA transfection reagent solution and incubated at room
temperature for 5 min. The siRNA ERβ/silMPORTER or the non-specific
siRNA /silMPORTER mixtures were then applied to the cells and incubated for
approximately 4 h. Thereafter, one ml of standard culture medium was added to
each well and incubated for another 48 h. The cells were harvested for
determination of the amounts of ERβ and Hps60 proteins. Initial experiments
were performed using three doses of siRNA-ERβ (50, 100 and 150 pmol/ml
culture medium) to determine the optimal siRNA-ERβ dose. These experiments
revealed that the siRNA-ERβ caused a dose-dependent reduction of ERβ
Fig. 2. Immunolocalization patterns of ERβ in MCF-10F Cells, trMCF, and MDA-MB-435 cells using LCSFM ERβ (green color) in MCF-10F, trMCF,
MCF-7 and MDA-MB-435 cells (panels 1, 4, 7 and 10, respectively) was identified with antibody ERβ Ab (SC) coupled to secondary antibodies (goat-
anti rabbit IgG) tagged with green fluorescent dye Fluor-488 (green Fluor 488). The cells probed with pre-immune IgG or without first antibody coupled
to the same secondary antibodies tagged with green Fluor 488 were shown in panels 13 and 16, respectively. Mitochondria (red color, panels 2, 5, 8, 11,
14 and 17) of these cells were identified d by MitoTracker. Merge is seen in intensive yellow in panels 3, 6 and 9 but not in panels 12, 15 and 18.
Arrows indicate nucleus.
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without causing detectable toxic effects. Time-dependent experiments were
performed to determine the duration of silencing of ERβ expression using the
optimal dose. Silencing of ERβ expression with this dose lasted for up to 96 h
after transfection with recovery to 60% reduction as compared to that of the non-
specific control group (data not shown). For confocal fluorescent microscopy
examination, the cells were processed as described above.
2.9. Ultrastructural localization of ERβ in trMCF and MCF-7 cells by
immunogold electron microscopy
The subcellular localization of ERβ in trMCF andMCF-7 cells was analyzed
by immunogold electron microscopy, which was performed according to
procedures previously described [25,61]. Cells were fixed in 4% formaldehyde
and pelleted. The cell pellet was infused with 2.3 M sucrose with 20%
polyvinylpyrrolidone (Sigma Chemical Co., St. Louis, MO) and frozen in liquidnitrogen. Ultrathin cryosections were cut using a Leica Ultracut UCT microtome
and placed on formvar coated nickel 200 mesh grids. The sections were blocked
with 10% FBS in PBS for 30 min and incubated with primary anti-ERβ rabbit
polyclonal antibody (Upstate, Cell Signaling Solutions-Millipore, Billerica,MA)
at a concentration of 10 μg/ml was followed by goat anti-rabbit gold IgG (6 nm)
(Jackson Immuno Research Laboratory, West Grove, PA) diluted 1:20 in PBS.
Final staining of the sections was done with 2%methylcellulose and 0.3% uranyl
acetate for 10 min at 4 °C. All sections were viewed and photographed on a
Philips CM 120 transmission electron microscope.
2.10. Statistical analysis
Each experiments was performed at least two times and some times
three times. Triplicate cultures were included in each treatment group. Data
are expressed as mean±SD and analyzed using the one-way ANOVA
program, and the differences were considered significant at pb0.05, as
Fig. 3. Co-localization of ERβ with a mitochondrial marker protein, COII and effects of silencing ERβ expression on the subcellular distributions of ERβ in
MCF-10F cells. (A) Silencing ERβ expression with ERβ-specific siRNA ERβ protein levels (upper panel) were first detected by Western blots. The protein
levels of Hsp60 (lower panel) were detected with Hsp60 antibody and used as protein loading control. Lanes 1 and 2, and lanes 3 and 4 represented sample from
an individual culture dish of the same experiments. Four separate ERβ silencing experiments were performed and similar results were obtained. (B) Immuno-
subcellular distribution of ERβ in MCF-10F cells detected via LSCFM: MCF-10F were transfected with non-specific siRNA (panels 1–3) or with ERβ specific
siRNA (panels 4–6), detected with ERβAb (SC) coupled to secondary antibodies (goat-anti rabbit IgG), which were tagged to green Fluor 488 and visualized
using LCSFM. Arrows indicate nucleus. The immunofluorescent experiments for the siRNA-ERβ and siRNA-control samples were performed in two separate
experiments and the results obtained were similar. (C) Immuno-subcellular distribution of ERβ in MCF-7 cells via LSCFM MCF-7 were transfected with non-
specific siRNA (panels 1–3) or with ERβ specific siRNA (panels 4–6) the same as described in panel C. The cells were probed with ERβAb (Upstate Cell
Signaling Solution) coupled to secondary antibodies (goat-anti rabbit IgG), which were tagged to green Fluor 488 and visualized using LCSFM. Arrows indicate
nucleus.
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comparisons.
3. Results
3.1. ERβ status in MCF-10F, trMCF, bsMCF and caMCF cells
The ERβ status in MCF-10F, trMCF, bsMCF and caMCF
cells was detected by Western blot using ERβ Ab(SC) (Fig.
1A). Protein extracts from MCF-7 cells and purified rhERβ
were included as positive controls for ERβ. This antibody
reacted with rhERβ (lane 1) and a protein with a molecular
size similar to that of rhERβ (59.7 kDa, indicated by the
arrow) in protein extracts prepared from MCF-10F (lane 2),trMCF (lane 3), bsMCF (lane 4), caMCF (lane 5) and MCF-7
cells (lane 6), indicating that ERβ protein is present in these
cells. For confirming these results, Western blots of proteins
prepared from the same sets of cells and T47D cells were
performed using ERβAb(SW) (Fig. 1B). This antibody
similarly reacted with rhERβ (lane 1) and protein samples
from MCF-7, MCF-10F, trMCF, bsMCF, caMCF and T47D
cells (lanes 3–8), respectively. These results indicate that a
major 59.7 kDa protein detected by both antibodies is present
in MCF-10F and MCF-10F sub-lines, which closely corre-
spond to the predicted molecular size of ERβ-1 isoform. In
addition, these results indicate that the ERβ levels in caMCF
cells appear to be lower than those of MCF-10F, trMCF and
bsMCF cells.
Fig. 4. Immunolocalization of ERβ via immunogold electron microscopy. (A) Photographs of immunogold electron microscopy for ERβ antibody-linked immunogold
particles in trMCF cells probed with ERβ antibody (Upstate Signaling Solutions). Panel 1 shows ERβ antibody-linked gold particles in the mitochondrial matrix
(arrows). The indicated area was amplified. Panel 2 shows a nucleus where no ERβ antibody-linked gold particles were detected. (B) Photographs of immunogold
electron microscopy for ERβ in MCF-7 cells probed ERβAb(SC). Panels 3 and 4 show a mitochondrion and a nucleus, respectively. Represent ERβ-antibody-linked
immunogold particles are indicated by the arrows. Scale bars and amplifications are shown.
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trMCF cells
The subcellular immunolocalization of ERβ was determined
by LCSFM in MCF-10F and trMCF cells using ERβ Ab(SC)
(Fig. 2). More than 300 MCF-10F cells were examined.
Typically, a weak green staining in their nuclei and a stronger
and punctate one in their cytoplasm were seen (Fig. 2, panel 1).
Mitochondria (red color) of these cells were specifically
identified with MitoTracker (Fig. 2, panel 2). When the
ERβ (green) and the mitochondria (red) were merged (panel
3), a large number of intense yellow spots become evident in the
cytoplasm, indicating the predominant co-localization of ERβ
immunostaining with MitoTracker staining. The majority
(N90%) of MCF-10F cells examined showed mitochondrial
ERβ. In trMCF cells the patterns of ERβ immunostaining (Fig.
2, panel 4), MitoTracker staining (Fig. 2, panel 5) and their
merge (Fig. 2, panel 3) were quite similar to those observed in
MCF-10F cells, indicating a minor presence of ERβ in the
nucleus and a predominant presence of ERβ in the mitochon-
dria of trMCF cells.
For verifying whether the predominant immunostaining of
ERβ in mitochondria of MCF-10F and trMCF cells was correct,we performed immunolocalization of ERβ in MCF-7 cells, in
which ERβ is known to be localized in both mitochondria and
nucleus [25,29,32]. Intensive green ERβ immunostaining was
seen in the nuclei (Fig. 2, panel 7). A moderate green ERβ
staining in cytoplasm was confirmed to be within mitochondria,
which were clearly identified by MitoTracker (Fig. 2, panel 8)
when merged with green staining of ERβ produced yellow
spots in the cytoplasm (Fig. 2 panel 9). More intensive ERβ
green immunostaining was present in their nuclei (Fig. 2, panel
9). These results are somewhat different from those previously
reported [25,62], in term of the nuclear ERβ immunostaining in
that more intensive nuclear staining was seen in this experiment.
These differences may be due to the different experimental
conditions. In the previous study [25], the confocal immuno-
fluorescent images were obtained with MCF-7 cells pre-treated
with E2, whereas in this study MCF-7 cells were not treated
without E2. Because the mitochondrial and nuclear levels of
ERα and ERβ were shown to be enhanced by E2 treatment,
with more enhanced distribution into mitochondria in MCF-7
cells [25], the different treatment of MCF-7 cells may account
for the observed differences in nuclear ERβ immunostaining.
These differences may also be due the variations in ER status
and ER distribution among MCF-7 cell variants used. For
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protein kinase C, ERα, ERβ status and estrogen signaling
among MCF-7 cell variants obtained from three laboratories,
which correlated with different apoptotic responses of the
corresponding MCF-7 cell variants. However, it is worthy to
emphasize that in spite of these differences in nuclear ERβ
immunostaining, the observed mitochondrial ERβ in MCF-7
cells is consistent with those reported previously [25,29,32].
Immunolocalization of ERβ in MDA-MB-435 cells, which
are both ERα and ERβ negative showed only weak background
(Fig. 2, panel 10) and absence of yellow spots in the cytoplasm
when MitoTraker stained mitochondria and ERβ-antibody
reacted cells were merged (Fig. 2, panels 11 and 12). MCF-
10F cells were probed with pre-immune rabbit IgG and served
as a negative control. Only very weak background green
staining was seen but no yellow spots were evident (Fig. 2,
panels 14, 14 and 15). Similar negative results were obtained
when MCF-10F cells were incubated without ERβ antibody
(Fig. 2, panels 16–18). These results indicate that ERβ is
predominantly localized in mitochondria, as specifically
detected with this anti-ERβ antibody.
3.3. Verification of mitochondrial localization of ERβ in
MCF-10F and trMCF cells
We then utilized two approaches to verify the mitochondrial
localization of ERβ in MCF-10F and trMCF cells. First, we
tested whether knocking down ERβ expression abolished the
nuclear and mitochondrial ERβ in these cells. MCF-10F cells
were transfected with ERβ-specific siRNA (siRNA-ERβ) or
with the equivalent amount of non-specific siRNA (as a
negative control). At 48 h after transfection, total protein
extracts were prepared from cells transfected with non-specific
siRNA or with siRNA-ERβ. Western blot analysis was first
performed to determine whether ERβ protein was indeed
knocked down by siRNA-ERβ. Equal amounts of protein
extracts (50 μg/lane) prepared from these cells were Western
blotted and probed with ERβ antibody. Transfection of MCF-
10F cells with siRNA-ERβ for 48 h dramatically reduced ERβ
protein levels (Fig. 3A, lanes 3 and 4) as compared to those of
cells transfected with non-specific siRNA (Fig. 3A, lanes 1 and
2). We next used LCSFM to examine the effects of silencing
ERβ protein expression on the subcellular distribution of ERβ.
The subcellular distribution of ERβ in cells transfected with
non-specific siRNA (Fig. 3B, panels 1–3) are quite similar to
those in normal MCF-10F cells (Fig. 2, panels 1–3). However,
in MCF-10F cells transfected with siRNA-ERβ, only weak
background is observed (Fig. 3B, panel 4). While mitochondria
are clearly stained by MitoTracker (Fig. 3B, panel 5), no yellow
spots are seen in cytoplasm when panels 4 and 5 are merged
(Fig. 3B, panel 6). These results are similar to those observed in
MDA-MB-435 cells which contain no detectable ERβ (Fig. 2,
panels 10–12) and indicate that silencing ERβ expression in
MCF-10F cells diminishes the green staining with ERβ
antibody in both nucleus and mitochondria, further proving
that ERβ is predominantly localized in mitochondria of these
cells.The effects of silencing ERβ expression with siRNA-ERβ
on subcellular distribution of ERβ in MCF-7 cells were also
examined. In MCF-7 cells transfected with non-specific siRNA,
the subcellular distribution patterns (Fig. 3C, panels 1–3) are
similar to those in normal MCF-7 cells (Fig. 2, panels 7–9).
However, in MCF-7 cells transfected with siRNA-ERβ, the
green staining intensity was reduced as compared to that in
MCF-7 cells transfected with non-specific siRNA (Fig. 3C,
panel 4 versus panel 1). While mitochondria are clearly stained
by MitoTracker (Fig. 3C, panel 5), only a few yellow spots are
seen in cytoplasm when panels 4 and 5 are merged (Fig. 3C,
panel 6), in contrast to the large number of yellow spots in
cytoplasm of the cells transfected with non-specific siRNA
(Fig. 3C, panel 3). These results support the previously
reported mitochondrial localization of ERβ in MCF-7 cells
[25,27,28,32].
Second, to provide more definitive confirmation for the
predominant mitochondrial localization of ERβ in trMCF cells
and to determine in which mitochondrial area(s) ERβ is
localized, we performed immunogold electron microscopy,
which has been utilized to determine the mitochondrial
localization of ERβ in MCF-7 and HepG2 cells [25,28].
TrMCF cells were probed with an ERβ antibody (Upstate Cell
Signaling Solution), which clearly detected ERβ protein in
these cells with Western blots and LCSFM (data not shown).
Representative Immunogold electron microphotographs were
shown in Fig. 4A. Gold particles were concentrated in certain
area(s) of mitochondrial matrix (Fig. 4A, panels 1, indicated by
arrow). Similar patterns are seen in the majority of mitochondria
examined (data not shown). However, very few to no ERβ-
linked immunogold particles were seen in the nucleus of the
majority of trMCF cells examined (e.g. Fig. 4A, panel 2). In
trMCF cells probed without ERβ antibody, no gold particles
were seen in either mitochondria or nucleus (data not shown).
These results are consistent with those detected by LCSFM
(Fig. 2, panels 4–6) and confirm the predominant mitochondrial
localization of ERβ in trMCF cells.
Immunolocalization of ERβ in MCF-7 cells was also
performed with ERβAb (SC) via immunogold electron
microscopy (Fig. 4B). A large number of ERβ-Ab-linked
gold particles were clearly seen in the mitochondrial matrix
(Fig. 4B, panel 3). However, unlike MCF-10F cells, ERβ Ab-
linked gold particles were also distributed in nuclei with more
concentration within the nucleolus (Fig. 4B, panel 4). These
results provide additional support for those detected with
confocal fluorescent microscopy (Fig. 2, panels 7–9) and
indicate that ERβ is present in mitochondria and nuclei of
MCF-7 cells.
3.4. ERβ shift from mitochondria to nucleus during E2-induced
transformation and tumorigenesis of HBEC
Since a various degrees of cytoplasmic and nuclear ERβ
have been seen between normal breast cells and breast cancer
cells [36–38], we next determined whether the subcellular
distribution of ERβ changed during the progression of E2-
induced transformation and tumorigenesis of HBEC. The
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ERβ antibodies against amino acid residues in the NH2-
terminal of human ERβ. To confirm the subcellular distribu-
tion patterns of ERβ among these cells, we used ERβAb
(SW), which was raised against the LBD of ERβ, to perform
subcellular immunolocalization of ERβ in MCF-10F and
trMCF cells and to compare them with those in the invasive
bsMCF and tumorigenic caMCF cells via LCSFM. The
subcellular immunolocalization patterns of ERβ in MCF-10F
and trMCF cells are shown in Fig. 5, panels 1–3 and Fig. 5,
panels 4–6, respectively. These patterns are almost identical
to those of the corresponding cell lines shown in Fig. 2,
panels 1–3 and panels 4–6, respectively. The representative
confocal fluorescent photomicrographs with bsMCF cells are
shown in Fig. 5, panels 7, 8 and 9. Unlike MCF-10F and
trMCF cells, moderate ERβ green staining was seen in the
cytoplasm and the relatively stronger ERβ green staining is
seen in the nuclei of these cells (panel 7). Mitochondria are
identified by MitoTracker (panel 8). A number of yellow
spots with moderate intensity are evident when the ERβ
green staining and the red staining by MitoTracker for
mitochondria are merged (panel 9), indicating the localizationFig. 5. Subcellular immunolocalization patterns of ERβ in MCF-10F, trMCF, bsMCF
MCF-10F, trMCF, bsMCF and caMCF cells (panels 1, 4, 7 and 10, respectively) wa
IgG), which were tagged with green Fluor 488. Mitochondria (red color, panels 2, 5,
yellow spots are seen in panel 3, 6, 9 and 12). Relatively intensive green is seen in t
(panels 7 and 9) and caMCF (panels 10 and 12) cells. Arrows indicate nuclei.of ERβ within mitochondria of these cells. In addition,
intensive green staining is evident in the nuclei of these cells
and in the nuclei of the majority of the cells examined. In
caMCF cells, a relatively weak green staining for ERβ is seen
in the cytoplasm but stronger green staining for ERβ is seen
in their nuclei (panel 10). Mitochondria are clearly detected
by MitoTracker (panel 11). When the ERβ green staining for
ERβ and the MitoTracker staining for mitochondria are
merged (panel 12), only weakly yellow spots are seen in
cytoplasm but more intensive ERβ green staining was seen in
the nucleus (indicated by arrows) of these cells, indicating
that more ERβ was concentrated in the nuclei than in
mitochondria of these cells. It should be noted that similar
subcellular immunolocalization patterns of ERβ in MCF-10F,
trMCF, bsMCF and caMCF cells were also detected using
ERβ Ab(SC) and ERβAb(GT) via LCSFM (data not shown).
Careful examination and comparison of the subcellular
immunolocalization patterns of ERβ among these cells
revealed a shift of ERβ from a predominantly mitochondrial
localization in MCF-10F and trMCF cells to a moderate
localization in both mitochondria and nucleus in bsMCF cells
to a nuclear localization in caMCF cells.and caMCF cells detected with ERβ Ab (SW) by LCSFM ERβ (green color) in
s identified with ERβAb(SW) coupled to secondary antibodies (goat-anti rabbit
8, and 11, respectively) of these cells were identified by MitoTracker. Intensive
he nuclei and relatively weak yellow spots are seen in the cytoplasm of bsMCF
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chain (MRC) proteins in MCF-10F cells by E2 and
ERβ-selective ligand, diarylpropionitrile (DPN)
It has been known that transcript levels of mtDNA-genes
are enhanced by E2 in a number of cell types [25,30,60,64–
69] and that these E2-induced effects in MCF-7 cells are
blocked by ER antagonist, ICI182,780, suggesting the
involvement of ERs in mediating these effects [25]. The
detection of predominant mitochondrial ERβ in MCF-10F
cells prompted us to determine whether mitochondrially
localized ERβ is directly involved in E2-induced expression
of mtDNA-encoded MRC proteins. We first examined the
dose-dependent effects of E2 on the transcript levels of three
mtDNA-genes, COI, CO II and ND1 (Fig. 6A). E2 dose-
dependently enhanced the transcript levels of these genes at
the concentrations ranging from 1 to 100 nM (Fig. 6A, panelsFig. 6. Stimulation of MRC protein expression in MCF-10F and bsMCF cells by E2
ND1. (I) Northern blot showing the dose-dependent effects of E2 on mRNA levels of
gel showing 28S and 18S rRNAs included as total RNA loading control. (II) Quan
indicated genes in Northern blot to that of the densitometry scan of 28S and 18S rRNA
DPN on mRNA levels of COI, CO II and ND1: (III) Northern blot for the indicated ge
and 18S rRNAs; (IV) Quantitative data: the ratio of the densitometry scans of the au
scan of 28S and 18S rRNAs, expressed as degree of induction over the control group.
indicated genes and the picture of corresponding ethidium bromide-stained gel showin
of the autoradiographs of the indicated genes in Northern blot to that of the densitome
group. (D) Effects of E2 and DPN on COII protein levels in MCF-10F cells: (VII) W
shown for protein loading. (VIII) Quantitative data: ratio of densitometry scans of th
actin, expressed as degree of induction over the control group. In panels A, C, E and G
are the representative of three and two separate experiments in MCF-10F cells and bs
⁎Indicates significantly greater than that of the control group (pb0.05, n=3).I and II). The transcript levels of COI and COII but not ND1
were significantly enhanced by E2 at 1 nM (Fig. 6A, panel
II). At 10 nM and 100 nM, the transcript levels of all three
genes were further enhanced by E2 by 2 to 3.5 fold over
those of the control group (Fig. 6A, panel II).
We then examined whether ERβ-selective ligand, DNP,
mimicked the stimulatory effects of E2 on the transcript levels
of these genes. The effects of E2 and DNP on the transcript
levels of these genes were compared. As expected, E2 enhanced
the mRNA levels of COI, COII and ND1 as compared to those
in control group (Fig. 6B, panel III, lanes 4–6 versus lanes 1–3)
by 1.7 to 2.5 fold (Fig. 6B, panel IV). Like E2, DPN
significantly enhanced mRNA levels of these genes over
those of control group by 2.0 to 2.5 fold (Fig. 6B, panel III,
lanes 7–9 versus lanes 1–3; Fig. 6B, panel IV). In parallel
experiments, we tested the effects of propylpyrazole triol (PPT),
an ERα-selective ligand [70], on the transcript levels of COIand DPN. (A) Dose-dependent effects of E2 on mRNA levels of COI, COII and
the genes indicates and a picture of the corresponding ethidium bromide-stained
titative data: the ratio of the densitometry scans of the autoradiographs of the
s, expressed as degree of induction over the control group. (B) Effects of E2 and
nes and the picture of corresponding ethidium bromide-stained gel showing 28S
toradiographs of the indicated genes in Northern blot to that of the densitometry
(C) Effects of PPTon transcript levels of COI and COII. (V) Northern blot for the
g 28S and 18S rRNAs; (VI) Quantitative data: the ratio of the densitometry scans
try scan of 28S and 18S rRNAs, expressed as degree of induction over the control
estern blotted for CO II protein levels in MCF-10F cells. The actin levels were
e autoradiographs of the indicated COII protein to that the densitometry scan of
, each lane represents a sample from a single culture dish. The results presented
MCF cells, respectively. In panels II, IV, VI and VII, bars show means±SD and
1741J.-Q. Chen et al. / Biochimica et Biophysica Acta 1773 (2007) 1732–1746and COII. Unlike E2 and DPN, 30 nM of PPT did not alter the
transcript levels of these genes (Fig. 6C). The ineffectiveness of
PPT in inducing the expression of these genes is likely due to
the lack of undetectable ERα in these cells. The effects of E2
and DPN on protein levels of COII in MCF-10F cells were
further examined. E2 and DPN significantly enhanced COII
protein levels by 2.2 and 3 fold, respectively, as compared to
those of control group (Fig. 6D).
All together, these results indicate that E2 and DPN at
physiological doses stimulate the mRNA and protein levels of
mtDNA-encoded MRC proteins and suggest that the mito-
chondrial ERβ is involved in these effects in MCF-10F cells.
3.6. Silencing ERβ expression blocked E2-induced synthesis of
COII protein
To definitively determine whether the mitochondrial ERβ
was required for these E2-mediated effects, we examined the
effects of silencing ERβ expression in mitochondria of
MCF-10F cells on E2-induced COII protein synthesis. MCF-
10F cells were first transfected with siRNA ERβ or with
non-specific siRNA for 48 h as described above. The protein
extracts prepared from these cells were Western blotted and
probed with ERβ antibody (Upstate Cell Signaling Solution)
and actin antibody, respectively. The ERβ protein levelsFig. 7. Silencing ERβ expression blocks E2-induced synthesis of COII protein in MC
specific siRNA as described in Fig. 3 and then treated with or without E2. (A) Silenc
transfected with non-specific siRNA. Lanes 4–6: samples from MCF-10F cells trans
culture dish. ERβ was detected with ERβ antibody obtained from Upstate Signaling S
Effects of E2 on CO II protein levels in MCF-10F cells transfected with non-specific si
E2 on CO II protein levels in MCF-10F cells transfected with ERβ-specific siRNA and
were included as protein loading control. Each lane represents sample from individua
on panels B and C: the ratio of densitometry scans of the autoradiographs of the indi
induction over the control group. ⁎Indicates significantly greater than that of the cowere almost totally reduced in MCF-10F cells transfected
with siRNA-ERβ (Fig. 7A, lanes 4–6) as compared to those
in MCF-10F cells transfected with non-specific siRNA (Fig.
7A, lanes 1–3). To determine the effects of silencing ERβ
expression on E2-induced MRC protein synthesis, the same
sets of cells were treated with or without E2 (10 nM) for
addition 36 h. As mentioned above, ERβ protein levels were
continually reduced up to 72 h with slight recovery at 96 h
after transfection with siRNA-ERβ. Protein samples prepared
from these cells were Western blotted and probed with COII
and actin antibodies, respectively. As expected, in MCF-10F
cells transfected with control siRNA, E2 enhanced COII
protein levels (Fig. 7B, lanes 4–6) by 2.5 fold (Fig. 7, panel
D) as compared to those of the cells without E2 treatment
(Fig. 7B, lanes 1–3). However, in MCF-10F cells transfected
with siRNA-ERβ, E2 caused only a slight increase in COII
protein levels (Fig. 7C, lanes 4–6 versus 7C, lanes 1–3 and
Fig. 7D). These results, together with those described above,
indicate that the mitochondrial ERβ in MCF-10F cells is
involved in E2-induced MRC protein synthesis.
4. Discussion
In the present study, we made three novel and important
findings: (1) ERβ is predominantly localized in mitochondria ofF-10F cells MCF-10F cells were transfected with non-specific siRNA and ERβ-
ing ERβ expression: Lanes 1–3: samples from MCF-10F cells transfected with
fected with ERβ-specific siRNA. Each lane represents samples from individual
olutions. The levels of actin protein were shown for protein loading control. (B)
RNA and then treated without (lanes 1–3) and with (lanes 4–6) E2. (C) Effects of
treated without (lanes 1–3) and with E2 (lanes 4–6). The protein levels of Actin
l culture dish. B and C were separate Western blots; (D) Quantitative data based
cated COII protein to that the densitometry scan of actin, expressed as degree of
ntrol group (pb0.05, n=3).
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ERβ shifts from the predominant mitochondrial localization to
nuclear localization during the progression of E2-induced
neoplastic transformation and tumorigenesis of HBEC; and
(3) the mitochondrial ERβ in MCF-10F cells is involved in E2-
induced expression of mtDNA-encoded MRC proteins.
The first finding that ERβ is predominantly localized in
mitochondria in the immortal MCF-10F and transformed
trMCF cells was made and confirmed by using several
complementary approaches. First, co-localization of ERβ
immunostaining with a mitochondria-specific dye, Mito-
Tracker, in both MCF-10F and trMCF cells was clearly
visualized by confocal fluorescent microscopy. In contrast,
this co-localization was seen neither in ERβ-negative MDA-
MB-435 cells nor in MCF-10F cells probed with pre-immune
IgG or without ERβ antibody. Second, even more convincingly,
we demonstrated that silencing the expression of ERβ with
siRNA-ERβ in MCF-10F and MCF-7 cells almost totally
diminished the ERβ in mitochondria and nuclei of these cells;
and third, ERβ antibody linked-gold particles present within the
mitochondrial matrix of trMCF cells were clearly visualized
under electron microscopy. These observations definitively
confirm to the previously reported mitochondrial ERβ in other
E2-target cells including human breast cancer MCF-7 cells
[25,32]. To our knowledge, this is the first report on the
predominant mitochondrial localization of ERβ in immortal and
transformed human breast epithelial cells. This finding is
somewhat different from the previously observed predominant
nuclear immunohistochemical staining of ERβ in both normal
human breast epithelial cells and pre-invasive/invasive breast
cancer cells [59]. These apparent discriminates may be due to
the different phenotypes of these cells and/or the use of different
ERβ antibodies and immunohistochemical methodologies.
However, Jarzabek et al. observed cytoplasmic and perinuclear
ERβ in normal and breast cancer cells [36]. Helguero et al. [71]
detected substantial cytoplasmic ERβ immunostaining in the
normal murine mammary epithelial cell line HC11.
The second novel and potentially important finding is that
ERβ shifts from predominant mitochondrial localization to
nuclear localization during progression of E2-induced transfor-
mation and tumorigenesis of HBEC. Because this shift is
similarly detected by using three different ERβ antibodies, it is
a trustworthy phenomenon at least in these in vitro/in vivo
HBEC models. More importantly, since these HBEC cell lines
are derived from the same origin, i.e. MCF-10F cells, and
represent immortal, transformed, invasive and tumorigenic
phenotypes [50], the shift of sub-cellular localizations of ERβ
among these cells is likely related to the phenotype changes and
pathogenesis during the progression of E2-induced HBEC
transformation and tumorigenesis. Whether this phenomenon is
a cause or a consequence of E2-induced neoplastic transforma-
tion of HBEC is not clear in the present study. However, a major
shift of ERβ from mitochondria to nucleus or from nucleus to
mitochondria can result in fundamental changes in the way cells
respond to E2 and anti-estrogens, causing alterations in the E2-
mediated cellular processes in mitochondria and nucleus.
Consistent with this notion, it was recently reported [72] thatlong-term treatment of MCF-7 cells with tamoxifen facilitated
the translocation of ERα out of the nuclei and enhanced its
interaction with epidermal growth factor receptor in the
cytoplasm. This change in ERα subcellular localization was
thought to be responsible for the acquired tamoxifen resistance.
Thus, the physiological, pathological and pharmacological
importance of this phenomenon warrants further investigation.
This finding is informative for subsequent studies on the
subcellular distribution and the physiological and pathological
role of ERβ in breast cancer cells where ERβ is expressed
alone. Two groups of ERβ-expressing human breast cancer
cells are known to date: one in which ERβ is co-expressed with
ERα and the other where ERβ is expressed alone [73]. The first
group comprises about 59% of primary human breast cancers
[74,75] whereas the second group comprises about 17%
[74,75]. There are data indicating different functions between
ERβ when it is expressed alone and when it is co-expressed
with ERα [73]. For example, Poola et al. [76] investigated the
expression of ERβ isoforms in ERα-negative breast cancer
tissues from African American patients. They observed
significant levels of ERβ1 and ERβ5 expressing in ERα-
negative tissues and significant differences between African
American and Caucasian breast cancer patients in that higher
levels of ERβ1 and ERβ5 but not ERα were expressed in breast
cancer tissues of some African American patients. Based on the
mitochondrial localization of ERβ observed in human breast
cancer cell lines [25,62] and HBEC as described in this study,
subsequent investigation of the subcellular distribution of ERβ
in human breast cancer tumors, particularly those of African
American breast cancer patients which contain ERβ isoforms
alone, is, therefore, of important and clinical relevance.
The third novel and important finding is that the
mitochondrial ERβ is involved in E2-induced synthesis of
mtDNA-encoded MRC proteins. Three lines of evidence lend
support for this finding. First, we demonstrated that E2 dose-
dependently stimulated the transcript levels of mtDNA genes,
COI, COII and ND1, in MCF-10F cells in which ERβ is
predominantly localized in mitochondria; Second, we
observed that the ERβ-selective ligand, DPN, mimicked E2
in enhancing the transcript levels of these genes as well as
protein levels of COII in these cells; and third, we found that
silencing ERβ expression in mitochondria of MCF-10F cells
blocked E2-induced COII protein synthesis. Consistent with
this finding, Hsieh et al. [64] observed up-regulation of MRC
complex IV by DPN acting via ERβ in rat cardiomyocytes.
However, Jonsson et al. [77] reported that the mitochondrial
ERβ was involved in E2-induced attenuation of COI
expression in human periodontal ligament cells. The up- or
down-regulation of mitochondrial proteins by E2 and ERβ
may be cell-type specific. Stirone et al. [78] detected ERα in
mitochondria of rat cerebral blood vessels and observed that
in vivo E2 treatment of ovariectatomized female rats increased
the levels of nuclear- and mtDNA-encoded MRC proteins in
cerebrovascular mitochondria, resulting in greater energy-
producing capacity in these cells. Recently, Gao et al. reported
that anorectic estrogenmimicked leptin, ametabolic hormone, in
up-regulation of energy metabolism in mouse brain [79]. These
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of mtDNA gene expression and MRC activity in a number of
cells including MCF-7 cells [25,27,78].
The displacement loop (D-loop) of human mtDNA, a major
regulatory region of mtDNA gene transcription, contains
estrogen responsive elements (mtEREs) [27,34,80]. It has
been shown that ERα and ERβ and ERβ in MCF-7 and MDA-
MB-231 mitochondrial extracts are capable of binding to these
mtEREs and that the binding of ERβ in mitochondrial extracts
to these mtEREs was enhanced by E2 in a dose- and time-
dependent manner [27]. The enhanced binding of MCF-7 cell
mitochondrial extracts to mtEREs [27] and the enhanced
transcript levels of mtDNA-genes by E2 [60] were detected as
early as three and 6 h after E2 treatment, respectively.
Furthermore, E2 enhanced the transcript levels of mitochondrial
transcript precursor from which the mature mitochondrial
RNAs including those of COI, CO II and ND1, are derived
[25,60]. All together, these observations indicate that the
mitochondrial ERα and ERβ play a direct role in E2-induced
expression of MRC proteins, at least, at transcriptional and
translational levels. It is of importance to determine the
molecular and cellular mechanisms underlying these E2/ER-
mediated mitochondrial effects. Because a number of cellular
processes such as cell proliferation, apoptosis, cell transforma-
tion and tumorigenesis are closely related to MRC functions, the
physiological and pathological implications of the E2-mediated
mitochondrial effects in these cellular processes warrant further
determination.
The molecular mechanisms underlying the shift in intracel-
lular localization of ERβ in normal and pathological conditions
are currently unknown. The intracellular distribution of ERβ is
dependent not only on sub-cellular localization signals encoded
in the receptor but also on the nature and composition of the
multi-molecular complexes formed by the receptor. The genetic
information for nuclear localization signal (NLS) for nuclear
localization, mitochondrial targeting polypeptide signal
(mtTPs) for mitochondrial targeting and membrane targeting
signal (mTS) for membrane targeting is generally encoded in
the amino acid sequences of proteins. For instance, human
ERα contains a NLS and mutations in this NLS abolish its
nuclear localization [47,81]. A putative NLS motif (RNRRR) is
present in the region of amino acid residues 195–199 of human
ERβ. The translocation of ERβ to plasma membrane and
nucleus remains to be understood. The predominant presence of
ERβ in mitochondria of MCF-10F and trMCF cells indicates
that this receptor has its own ability to enter mitochondria.
Proteins targeting mitochondria usually contain mtTPs in their
NH2-terminal pre-sequences or in their carboxyl-terminal
sequences [82]. Some mitochondrial proteins, e.g. BCS1 [83],
contain mtTPs in their internal sequences. A putative internal
mtTPs has been identified in human ERβ [25] and a similar
internal mtTPs is present in glucocorticoid receptor that is
localized in mitochondria [84], suggesting that ERβ may have
intrinsic potential to enter mitochondria. The differential
localizations of ERβ among these MCF-10F cell lines indicate
that in addition to the NLS and mtTPs, the differences in the
nature and composition of the multi-molecular complexesformed by the receptor, i.e. the nuclear localization complex and
the mitochondrial import machinery, may contribute to the
differential localizations of ERβ among the MCF-10F cell lines.
While mutations in NLS and mtTPs motif in ERβ proteins may
alter the subcellular distribution of this receptor, it is likely that
some key protein factors expressing in MCF-10F and trMCF
cells are involved in the mitochondrial import of ERβ in these
cells whereas these proteins may be defective in caMCF cells.
Additionally, the status of the posttranslational modifications of
ERβ itself, such as alternative glycosylation and phosphoryla-
tion [85–87], may alter its subcellular localization among these
cells, because the status of glycosylation [88,89] and phosphor-
ylation [90] of proteins, e.g. phosphorylated glucocorticoid
receptor [91], can influence their subcellular localization. Thus,
it is crucial to identify the key factors contributing to different
subcellular localization of ERβ among these cell lines and to
elucidate the molecular mechanisms underlying the nuclear
localization and mitochondrial import of ERβ.
The predominant presence of ERβ in mitochondria of
immortal and transformed HBEC, its role in E2-induced
mtDNA transcription, and potential implications in the control
of cellular processes are pathologically relevant in human breast
cells which are at prolonged exposure to relatively higher E2
levels due to the in situ E2 synthesis [92]. Persistent stimulation
of these mitochondrial effects in HBEC may contribute to
increased breast cancer risk by altering energy-related
physiological processes, e.g. cell proliferation, cell cycle,
apoptosis and transformation. Thus, to determine the precise
role of these effects in the progression of HBEC transforma-
tion and tumorigenesis is particularly valuable for exploration
of new intervention approaches to breast cancer treatment that
target E2/ERβ-mediated MRC protein synthesis and energy
metabolism.
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